Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.13), $0.11 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $3.68 million versus the consensus estimate of $2.3 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.